Markets
Will the CDC announce a public health advisory about a cyclosporiasis outbreak linked to lettuce by July 31, 2026?
Yes0%No0%
Loading...
About this market
This market resolves to Yes if the U.S. Centers for Disease Control and Prevention (CDC) issues a formal public health advisory related to a multistate cyclosporiasis outbreak linked to lettuce by the end of July 31, 2026. The advisory must specifically mention lettuce as a confirmed vehicle of transmission. The market resolves to No if no such advisory is issued by that date.
Rules
- Market closes at 7/31/2026.
- Logic weighted resolution applies.
Other open markets in Health
Will WHO recommend a new global initiative to reduce dementia risk by October 1, 2026?
This market resolves to Yes if the World Health Organization (WHO) publicly announces a new global initiative specifically aimed at reducing dementia risk (e.g., through actionable guidelines, public campaigns, or research funding) by October 1, 2026. This initiative must go beyond existing dementia-related recommendations or programs and involve a formal new announcement from the WHO.
Will the WHO's Europe Regional Office finalize and publish its new digital health strategy by August 31, 2026?
This market resolves to Yes if the WHO's Europe Regional Office publicly announces the finalization and publication of its new digital health strategy by August 31, 2026. The resolution will be based on official and verifiable announcements from the WHO Regional Office for Europe or relevant trusted media sources. If no announcement is made by this date, the market resolves to No.
Will WHO's global digital health strategy be released by July 31, 2026?
This market resolves to Yes if the World Health Organization (WHO) publicly releases its global digital health strategy by July 31, 2026. Any official statement, publication, or press release confirming the release will constitute resolution. A lack of announcement or confirmation by this date resolves the market to No.
Will the FDA approve the first osteo-arthritis regenerative injection therapy by August 31, 2026?
This market resolves to Yes if the U.S. Food and Drug Administration (FDA) announces formal approval of the first regenerative injection therapy for osteo-arthritis, as described in recent research news, by August 31, 2026. Any official FDA announcement, press release, or public database update confirming approval will determine the outcome. If no such approval is granted by the close date, the market resolves to No.
Will Linear Health Sciences' Orchid SRV be launched in Japan by July 22, 2026?
This market resolves to Yes if Linear Health Sciences and NIPRO CORPORATION launch the Orchid Safety Release Valve (SRV) in the Japanese market on or before July 22, 2026, as per their announcement. The launch must involve public confirmation of product availability in Japan or sales starting by the specified date, confirmed through media reports or an official press release.
Will the NICE-recommended non-invasive tests for endometriosis be implemented in NHS pilot studies by August 31, 2026?
This market resolves to Yes if it is confirmed that the National Health Service (NHS) has begun pilot studies implementing the non-invasive tests for endometriosis recommended by NICE (National Institute for Health and Care Excellence) by August 31, 2026. Public confirmation may come from NHS press releases, reputable UK health media outlets, or official NICE/NHS communications.